angiotensin II
Giapreza · ATC code C09
- Key facts
- Active substance
- angiotensin II
- ATC code
- C09
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Giapreza 2.5 mg/ml concentrate for solution for infusion
- Marketing authorisation holder
- Paion Pharma GmbH
- Information as of
- 2026-10-27
Key facts
Angiotensin II is a vasopressor (synthetic peptide hormone). It is used in adults with refractory hypotension in septic or other distributive shock.
What it is used for
- Refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution, catecholamines and other available vasopressor therapies
Dosing
- Hospital use only, by physicians experienced in treating shock; continuous intravenous infusion after dilution, preferably via a central venous line
- Starting dose: 20 ng/kg per minute
- May be titrated as often as every 5 minutes in steps of up to 15 ng/kg per minute, according to target MAP (usually 65–75 mmHg)
- Do not exceed 80 ng/kg per minute during the first 3 hours; maintenance doses not above 40 ng/kg per minute
- Withdraw gradually in decrements of up to 15 ng/kg per minute to avoid hypotension
- No special dose adjustment in the elderly or in renal or hepatic impairment; no data in children
Contraindications
- Hypersensitivity to the active substance or any excipient
Important warnings
- Clinical experience limited to septic or other distributive shock; not recommended in other shock types (e.g. cardiogenic shock)
- Thromboembolic events; concurrent VTE prophylaxis unless contraindicated
- Peripheral ischaemia; use the lowest compatible dose
- Abrupt withdrawal may cause hypotension or worsening of shock
Side effects
- Very common: thromboembolic events, transient hypertension
- Common: tachycardia, peripheral ischaemia
- Transient hypertension at the starting dose may be promptly mitigated by down-titration
Interactions
- Recent ACE inhibitors: possibly increased response
- Recent angiotensin II receptor blockers: possibly reduced response
- Other vasopressors: additive effect on MAP; their doses may need reduction
Pregnancy and breastfeeding
- Pregnancy: limited data; avoid if possible and weigh benefit against possible fetal risk
- Breast-feeding should be discontinued during treatment
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- GiaprezaPaion Pharma GmbH · EMEA/H/C/004930
Source: European Medicines Agency (EMA), product information
Brand names in 3 more European countries
- Iceland
- Giapreza
- Liechtenstein
- Giapreza
- Norway
- Giapreza
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Related calculators
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Giapreza – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/giapreza-epar-product-information_en.pdf
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.